Arrhythmogenic right ventricular dysplasia/cardiomyopathy – Three decades of progress

Research output: Contribution to journalArticle

Abstract

Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a rare, inherited cardiomyopathy characterized by ventricular arrhythmias, sudden cardiac death, and right ventricular dysfunction. Since the first major description of this disease, much has been learned about ARVD/C. One of the main breakthroughs was the discovery that mutations in desmosomal proteins are the most frequent genetic basis of ARVD/C. Today, genetic testing plays an important role in both the diagnosis of ARVD/C and cascade family screening. Much has also been learned concerning the optimal approaches to diagnosis. The 2010 Task Force Diagnostic criteria for ARVD/C represent the standard for diagnosis today. We have also learned much about the importance of proband status and the 24-h PVC count to assess sudden death risk, and the importance of exercise both in the development of ARVD/C in susceptible individuals and in defining the course of the disease. From a treatment perspective, placement of ICDs in specific subsets of patients with ARVD/C who are at increased risk of sudden death is important. The techniques of VT ablation have also evolved over time and are valuable components of our management strategies for the ARVD/C patient today. This review will provide an update on ARVD/C, with specific attention to some of the contributions to this field reported by the Johns Hopkins ARVD/C Program.

Original languageEnglish (US)
Pages (from-to)901-913
Number of pages13
JournalCirculation Journal
Volume79
Issue number5
DOIs
StatePublished - 2015

Fingerprint

Arrhythmogenic Right Ventricular Dysplasia
Sudden Death
Ablation Techniques
Right Ventricular Dysfunction
Sudden Cardiac Death
Genetic Testing
Advisory Committees
Cardiomyopathies
Polyvinyl Chloride
Cardiac Arrhythmias
Exercise

Keywords

  • Ablation
  • Cardiomyopathy
  • Exercise
  • Ventricular arrhythmia
  • Ventricular fibrillation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Arrhythmogenic right ventricular dysplasia/cardiomyopathy – Three decades of progress. / Calkins, Hugh.

In: Circulation Journal, Vol. 79, No. 5, 2015, p. 901-913.

Research output: Contribution to journalArticle

@article{c1bc3003bcc948ad86a0e99ce614b3e6,
title = "Arrhythmogenic right ventricular dysplasia/cardiomyopathy – Three decades of progress",
abstract = "Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a rare, inherited cardiomyopathy characterized by ventricular arrhythmias, sudden cardiac death, and right ventricular dysfunction. Since the first major description of this disease, much has been learned about ARVD/C. One of the main breakthroughs was the discovery that mutations in desmosomal proteins are the most frequent genetic basis of ARVD/C. Today, genetic testing plays an important role in both the diagnosis of ARVD/C and cascade family screening. Much has also been learned concerning the optimal approaches to diagnosis. The 2010 Task Force Diagnostic criteria for ARVD/C represent the standard for diagnosis today. We have also learned much about the importance of proband status and the 24-h PVC count to assess sudden death risk, and the importance of exercise both in the development of ARVD/C in susceptible individuals and in defining the course of the disease. From a treatment perspective, placement of ICDs in specific subsets of patients with ARVD/C who are at increased risk of sudden death is important. The techniques of VT ablation have also evolved over time and are valuable components of our management strategies for the ARVD/C patient today. This review will provide an update on ARVD/C, with specific attention to some of the contributions to this field reported by the Johns Hopkins ARVD/C Program.",
keywords = "Ablation, Cardiomyopathy, Exercise, Ventricular arrhythmia, Ventricular fibrillation",
author = "Hugh Calkins",
year = "2015",
doi = "10.1253/circj.CJ-15-0288",
language = "English (US)",
volume = "79",
pages = "901--913",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "5",

}

TY - JOUR

T1 - Arrhythmogenic right ventricular dysplasia/cardiomyopathy – Three decades of progress

AU - Calkins, Hugh

PY - 2015

Y1 - 2015

N2 - Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a rare, inherited cardiomyopathy characterized by ventricular arrhythmias, sudden cardiac death, and right ventricular dysfunction. Since the first major description of this disease, much has been learned about ARVD/C. One of the main breakthroughs was the discovery that mutations in desmosomal proteins are the most frequent genetic basis of ARVD/C. Today, genetic testing plays an important role in both the diagnosis of ARVD/C and cascade family screening. Much has also been learned concerning the optimal approaches to diagnosis. The 2010 Task Force Diagnostic criteria for ARVD/C represent the standard for diagnosis today. We have also learned much about the importance of proband status and the 24-h PVC count to assess sudden death risk, and the importance of exercise both in the development of ARVD/C in susceptible individuals and in defining the course of the disease. From a treatment perspective, placement of ICDs in specific subsets of patients with ARVD/C who are at increased risk of sudden death is important. The techniques of VT ablation have also evolved over time and are valuable components of our management strategies for the ARVD/C patient today. This review will provide an update on ARVD/C, with specific attention to some of the contributions to this field reported by the Johns Hopkins ARVD/C Program.

AB - Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a rare, inherited cardiomyopathy characterized by ventricular arrhythmias, sudden cardiac death, and right ventricular dysfunction. Since the first major description of this disease, much has been learned about ARVD/C. One of the main breakthroughs was the discovery that mutations in desmosomal proteins are the most frequent genetic basis of ARVD/C. Today, genetic testing plays an important role in both the diagnosis of ARVD/C and cascade family screening. Much has also been learned concerning the optimal approaches to diagnosis. The 2010 Task Force Diagnostic criteria for ARVD/C represent the standard for diagnosis today. We have also learned much about the importance of proband status and the 24-h PVC count to assess sudden death risk, and the importance of exercise both in the development of ARVD/C in susceptible individuals and in defining the course of the disease. From a treatment perspective, placement of ICDs in specific subsets of patients with ARVD/C who are at increased risk of sudden death is important. The techniques of VT ablation have also evolved over time and are valuable components of our management strategies for the ARVD/C patient today. This review will provide an update on ARVD/C, with specific attention to some of the contributions to this field reported by the Johns Hopkins ARVD/C Program.

KW - Ablation

KW - Cardiomyopathy

KW - Exercise

KW - Ventricular arrhythmia

KW - Ventricular fibrillation

UR - http://www.scopus.com/inward/record.url?scp=84928474007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928474007&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-15-0288

DO - 10.1253/circj.CJ-15-0288

M3 - Article

VL - 79

SP - 901

EP - 913

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 5

ER -